Clinical Trial Update: Evaluation of the Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the metabolic effects of LCZ696 (sacubitril/valsartan) compared with amlodipine in obese hypertensive subjects; results have been poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension
• Obesity

Drugs mentioned

• Amlodipine (amlodipine)
• LCZ696 (sacubitril/valsartan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hypertension, Concurrent Obesity | Phase 2 | Status: COMPLETED | Results posted: 2015-08-10